

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/728,275 |
| | | | | Filing Date | December 4, 2003 |
| | | | | First Named Inventor | Atul Varadhachary |
| | | | | Art Unit | N/A |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 1 | Attorney Docket Number | HO-P02726US2 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| <i>AK</i> | AA | US-20020119928 | 08-29-2002 | McAnalley | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|--------------------------------|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ³ |
| | | Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| <i>AK</i> | BA | WO-0241912 | 05-30-2002 | Nuclear Receptor Research limited | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|--|----------------|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| <i>AK</i> | CA | Kajikawa et al, "Lactoferrin inhibits Cholesterol Accumulation in Macrophages Mediated by Acetylated or Oxidized Low-Density Lipoproteins," Biochim Biophys Acta. 1994 jun 23; 1213(1): 82-90. | | |
| | CB | Croy et al, "All three LDL Receptor Homology Regions of the LDL Receptor-related Protein Binf Multiple Ligands," Biochemistry 2003 Nov. 11; 42(44): 13049-13057. | | |
| | CC | Huettinger, M. et al, "The LDL-receptor Family: Lactoferrin and Lipid Metabolism," Adv Exp. Med Biol. 1998; 443: 107-11. | | |
| | CD | Huettinger, m. et al, "Characteristics of Chylomicron Remnant Uptake into Rat Liver," Clin Biochem. 1988 April; 21(2): 87-92. | | |
| | CE | van Dijk MC et al, "Recognition of Chylomicron Remnants and Beta-Migrating very-low Density Lipoproteins by the Remnant Receptor of Parenchymal Liver Cells is Distinct from the Liver Alpha 2-Macroglobulin Recognition Site," Biochem J. 1991 no. 1; 279(Pt. 3): 863-70. | | |
| | CF | Benezra, M. et al, "A Synthetic Heparin-Mimicking Polyanionic Compound Binds to the LDL Receptor-related Protein and inhibits Vascular Smooth Muscle Cell Proliferation," J. Cell Biochem 2001; 81(1): 114-27. | | |
| | CG | Hayashida et al, "Bovine Lactoferrin has a Nitric Oxide-dependent Hypotensive Effect in Rats," Am J Physiol Regul Integr Comp Physiol. 2004 Feb.; 286(2): R359-65. | | |
| <i>AK</i> | CH | Llirbat et al, "Normal and Inhibited Cholesterol Synthesis in the Cultured Rat Embryo," Journal of Lipid Research Vol. 38, pp. 22-34 (1997). | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.








| | | | |
|-----------------------|--------------------------|--------------------|---------|
| Examiner Signature | <i>Atul Varadhachary</i> | Date Considered | 3/16/05 |
|-----------------------|--------------------------|--------------------|---------|



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

| Title of Invention | LACTOFERRIN IN THE REDUCTION OF CIRCULATING CHOLESTEROL, VASCULAR INFLAMMATION,ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE | | | | | | | | | | | | | | | | | | | | |
|--|--|-------------|------------|--------------|------|-----------|----------|-------|----------|---|----|-------------|------------|--------------|--|--|--|---------------|------|---|---------|
| <p>Application Number: 10/728275 </p> <p>Confirmation Number: 7126</p> <p>First Named Applicant: Atul Varadhachary</p> <p>Attorney Docket Number: HO-P02726US2</p> <p>Art Unit: N/A</p> <p>Examiner: Not Yet Assigned</p> <p>Search string: (20030060425).pn.</p> <p>US Published Applications</p> <p>Note: Applicant is not required to submit a paper copy of cited US Published Applications.</p> <table border="1"><thead><tr><th>init</th><th>Cite.No.</th><th>Pub. No.</th><th>Date</th><th>Applicant</th><th>Kind</th><th>Class</th><th>Subclass</th></tr></thead><tbody><tr><td></td><td>AA</td><td>20030060425</td><td>2003-03-27</td><td>Ahlem et al.</td><td></td><td></td><td></td></tr></tbody></table> <p>Signature</p> <table border="1"><thead><tr><th>Examiner Name</th><th>Date</th></tr></thead><tbody><tr><td></td><td>3/16/05</td></tr></tbody></table> | | init | Cite.No. | Pub. No. | Date | Applicant | Kind | Class | Subclass |  | AA | 20030060425 | 2003-03-27 | Ahlem et al. | | | | Examiner Name | Date |  | 3/16/05 |
| init | Cite.No. | Pub. No. | Date | Applicant | Kind | Class | Subclass | | | | | | | | | | | | | | |
|  | AA | 20030060425 | 2003-03-27 | Ahlem et al. | | | | | | | | | | | | | | | | | |
| Examiner Name | Date | | | | | | | | | | | | | | | | | | | | |
|  | 3/16/05 | | | | | | | | | | | | | | | | | | | | |